MedTrace Logo

Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

NCT03264651 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-04-18

No results posted yet for this study

Summary

To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.

Conditions

  • Mammographic Density

Interventions

DRUG

enobosarm

Oral combination therapy of enobosarm and anastrozole

Sponsors & Collaborators

  • GTx

    collaborator INDUSTRY

  • Havah Therapeutics Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Stephen N Birrell, MD PhD · Havah Therapeutics Pty Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2018-03-21
Completion
2018-03-21

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03264651 on ClinicalTrials.gov